Business
Merck Quashes Fourth-Quarter Calls, But 2026 Guidance Rattles Shares
Merck (MRK) quashed fourth-quarter expectations Tuesday morning on the back of a solid Keytruda beat, but the Dow Jones health giant issued lackluster expectations for 2026 as its Gardasil challenges continue. For the year, Merck said it expects to earn an adjusted $5 to $5.15 per share, completely missing the Street’s call for $5.27. The company said the guidance includes…